FGFR Pathway Inhibition in Gastric Cancer: The Golden Era of an Old Target?
Csongor György LengyelSadaqat HussainAndreas SeeberSara Jamil NidhamalddinDario TrapaniBaker Shalal HabeebEssam ElfahamSyed Ayub MazherFahmi Usman SeidShah Zeb KhanKhalid El BairiAndrew OdhiamboSara C AltunaAngelica PetrilloPublished in: Life (Basel, Switzerland) (2022)
Gastric cancer (GC) is the third leading cause of cancer-associated death worldwide. The majority of patients are diagnosed at an advanced/metastatic stage of disease due to a lack of specific symptoms and lack of screening programs, especially in Western countries. Thus, despite the improvement in GC therapeutic opportunities, the survival is disappointing, and the definition of the optimal treatment is still an unmet need. Novel diagnostic techniques were developed in clinical trials in order to characterize the genetic profile of GCs and new potential molecular pathways, such as the Fibroblast Growth Factor Receptor (FGFR) pathway, were identified in order to improve patient's survival by using target therapies. The aim of this review is to summarize the role and the impact of FGFR signaling in GC and to provide an overview regarding the potential effectiveness of anti-FGFR agents in GC treatment in the context of precision medicine.
Keyphrases
- clinical trial
- end stage renal disease
- randomized controlled trial
- gas chromatography
- small cell lung cancer
- systematic review
- squamous cell carcinoma
- public health
- gene expression
- chronic kidney disease
- south africa
- case report
- climate change
- mass spectrometry
- peritoneal dialysis
- sleep quality
- study protocol
- phase ii
- patient reported outcomes
- double blind
- smoking cessation
- phase iii
- tandem mass spectrometry
- placebo controlled